Initial Testing (Stage 1) of Tazemetostat (EPZ-6438), a Novel EZH2 Inhibitor, by the Pediatric Preclinical Testing Program

BACKGROUND: Tazemetostat (EPZ-6438) is a selective inhibitor of the histone methyltransferase EZH2, currently in clinical development for non-Hodgkin lymphoma and genetically defined tumors. PROCEDURES: Tazemetostat was tested against the PPTP solid tumor xenografts using a dose of 400 mg/kg adminis...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Pediatr Blood Cancer
Main Authors: Kurmasheva, Raushan T., Sammons, Melissa, Favours, Edward, Wu, Jianwrong, Kurmashev, Dias, Cosmopoulos, Katherine, Keilhack, Heike, Klaus, Christine R., Houghton, Peter J., Smith, Malcolm A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5584632/
https://ncbi.nlm.nih.gov/pubmed/27555605
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.26218
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados